Synthetic Biology: Recent Trends & Research

News and Trends 7 Oct 2015

Sorry CRISPR, you’ll have to wait another year to win a Nobel Prize!

The first paper on CRISPR gene editing tech was only published in 2012. As a key player in the biotech revolution, CRISPR is the discovery of the century, permitting a whole new field of gene-editing for therapeutic purposes in a range of different research areas. Two of those responsible for the existence of CRISPR-Cas9, Jennifer […]

October 7, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 6 Oct 2015

An Insider’s experience at the iGEM Giant Boston Jamboree 2015

Last week, our Guest blogger Matthieu de Costa (LinkedIn here) attended the iGEM Giant Jamboree at the Hynes Convention Center in Boston (MA). As part of the IONIS iGEM Team from the Sup’Biotech Institute for Biotechnology in Paris (France), his team came back with a Gold medal for their Bio-console video game which aims to […]

October 6, 2015 - 4 minutesmins - By Dani Bancroft

News and Trends 5 Oct 2015

iGEM 2015: Europe still dominates World’s Largest Synthetic Biology Contest

The iGEM 2015 results are out! The World’s largest synthetic biology competition (24th – 28th September) held in Boston (US) has yet again shown up a great European representation in the winning teams. Divided into 3 tiers (Post-graduate, Under-graduate and High-School) winners and their projects are listed below. Originally launched by Massachusetts Institute for Technology […]

October 5, 2015 - 4 minutesmins - By Dani Bancroft

News and Trends 2 Oct 2015

Algaemy Fashion: Use of microalgae by Berlin textile design Duo

Berlin-based designers have discovered the aesthetic appeal of manipulating microalgae to produce inks for textile printing. Inspired by work in the German biotech industry, the designer duo was recently subject of a Ted talk praising their creative efforts in founding Algaemy. After visiting the Fraunhofer Institute for Interfacial Engineering and Biotechnology in Munich, Rasa Weber […]

October 2, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 29 Sep 2015

Could an Alpaca’s monoclonal antibodies be used to treat an ultra-rare blood disease?

Ablynx‘s Nanobody platform has used the smaller than human monoclonal antibodies from an alpaca to develop the phase III Orphan designated drug Caplacizumab. A phase III study ‘Hercules’ is now pioneering Caplacizumab as the first ever anti-Von Willebrand factor (vWF) nanobody for treating an ultra-rare blood clotting disorder. Caplacizumab is a pioneering monoclonal antibody (mAb) […]

September 29, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 28 Sep 2015

Bio-mining the Diversity of Deserts: A Biotech industry Goldmine

Deserts can be either hot or cold according to their geographical location, leading to the evolution of extremophilic organisms which are adapted to withstand such hostile living conditions. Here, we explore some of the potential industrial biotech applications of desert microbes, from bioremediation of pollutants such as PCP, to the investigation of novel anti-cancer compounds. […]

September 28, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 21 Sep 2015

How can we increase the nutritional value of GMO-rice whilst cutting greenhouse emissions?

New GMO rice variety has an increased starch content coupled with low greenhouse gas emissions. By making these GM rices more eco-friendly as well as improving their nutritional value, this research could potentially sway the public and political stigma against this life-altering technology, in the mission to save millions. As we all know, grains such as Golden […]

September 21, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 11 Sep 2015

Biofuels from tobacco: US Tyton and French Deinove partner up

The French green Biotech Deinove continues to strengthen its position in the New World after sealing a new agreement with an American company. Deinove and Tyton BioEnergy systems will bring new solutions to the green chemicals market sector. Deinove’s technology platform produces biofuels and bio-based chemicals by using Deinococcus bacteria as host strains. The bioprocess […]

September 11, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 27 Aug 2015

The 5 things outside Europe you need to know this week (Samsung $1Bn Biotech IPO, Microbiome blindness, Google Biotech)

Hi there! Here are the 5 most important Biotech things that happened outside Europe in the last few days. Enjoy and share! Samsung, Biogen lining up a $1B IPO for biosimilar joint venture: WSJ Samsung is also interested in Biotech and more precisely in Biosimilars. It created a joint-venture with Biogen and now wants to […]

August 27, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 12 Aug 2015

CRISPR Therapeutics reinforces its Team with Top Executives from Pfizer and McKinsey

A new strategic movement in the hot CRISPR field: CRISPR Therapeutics ramps up its leadership team with Samarth Kulkarni as its new Chief Business Officer and Michael Bruce as Senior Vice President to moderate program portfolio and alliance management. In the meantime, CRISPR’s main competitor EditasMedicine procured €108M to accelerate its CRISPR-based therapies in clinical state. […]

August 12, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 11 Aug 2015

Pili Printed their First Page with Bacteria-Made Ink!

Pili is a group of seven young dedicated entrepreneurs that dream of replacing the toxic pigments used in today’s ink with natural, non-toxic, recyclable ink made by bacteria. A dream that could soon become reality as the start-up just achieved the first proof of concept and printed its first page with a bacteria-made biodegradable ink! It […]

August 11, 2015 - 3 minutesmins - By Philip Hemme

News and Trends 9 Aug 2015

Fresh Money for a Chlamydia Vaccine Using Synthetic Biology

Prokarium Ltd today announced a new £377k (€534k) funding from SynbiCITE to develop an innovative Chlamydia vaccine using synthetic biology. The new therapy could help the 92 million people affected by Chlamydia each year and help fighting one of the most common sexually transmitted infections. The £498k (€706k) Chlamydia vaccine project is funded at £377k (€534k) from SynbiCITE, the UK’s Innovation and […]

August 9, 2015 - 3 minutesmins - By Joachim Eeckhout

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us